Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Prospective multicenter, open-lab el, observational, single arm study of decitabine. Subjects
will be elderly patients with newly diagnosed, treatment-naïve AML who are unfit to receive
and not candidate for intensive induction chemotherapy (iIC)
Details
Lead Sponsor:
Ulsan University Hospital
Collaborator:
The Korean Society of Hematology, AML/MDS Working Party